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Over the past decade, standard first-line systemic treatment of advanced hepatocellular 
carcinoma (HCC) has been based on sorafenib, a multi-kinase inhibitor. Regorafenib, another 
tyrosine kinase inhibitor, is the only second-line therapy that has been globally approved after 
progression under sorafenib treatment. Recently, immunotherapeutic agents have emerged 
as promising treatment options in many different malignancies, including advanced HCC. 
Nivolumab is the first immunotherapy approved by the Food and Drug Administration for 
use in HCC patients with advanced-stage second-line after sorafenib failure. In this report, 
a case of advanced HCC with multiple lung metastases in which a complete response and 
maintained progression-free status was achieved with nivolumab, following the failure of 
transarterial chemoembolization and sorafenib is presented. We hope this report may help 
expand the clinical application of second-line treatment.  (J Liver Cancer 2020;20:72-77)
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Hepatocellular carcinoma (HCC) is the most common 
primary malignant tumor in the liver and the second most 
frequent cause of cancer-related death globally.1 In Korea, 
HCC has the highest mortality rate in the working-age popu-
lation, and the greatest economic burden of cancer.2 Surgical 
treatment or local ablation is the only curative therapy for lo-
calized disease. Therapeutic options for advanced disease are 
even more limited.1-3 Sorafenib, the first molecularly targeted 
systemic agent for advanced liver cancer, has remained the 
primary treatment option since 2007.4-6 Another multi-ki-
nase inhibitor, regorafenib, was approved for the treatment 
of HCC patients who have been previously treated with 
sorafenib but showed limited survival benefits.7 A more ef-
fective systemic treatment option for advanced HCC is 
strongly warranted. In recent years, new immune-modulato-
ry agents have been introduced for the oncological treatment 
of various solid malignancies. Immune checkpoint proteins, 
inhibiting the interaction between programmed death recep-
tor 1 (PD-1) and its ligand have shown substantial survival 
benefits in many different malignancies.8-10 Nivolumab, as a 
novel immune checkpoint inhibitor, is increasingly used in 
patients with cancer, in particular for those with melanoma. 
Nivolumab is currently being evaluated in relation to a num-
ber of other cancers such as metastatic non-small cell lung 
cancer following treatment failure of platinum-based chemo-
therapy, advanced renal cell cancer and squamous cell carci-
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noma of the head and neck.11-13 This treatment can lead to a 
powerful multi-target immune response that can induce per-
sistent oncological remission in some patients. A phase I/II 
CheckMate-040 study investigated nivolumab treatment in 
patients with advanced HCC. In the dose-expansion phase of 
this study, patients received nivolumab 3 mg/kg, and the ob-
jective response rate was 20%, with a median duration of re-
sponse of 9.9 months and a 9-months overall survival rate of 
74%.14 The nivolumab safety profile was consistent with that 
observed in other tumor types, and no new safety signals 
were observed. Here, we report a case of advanced HCC with 
multiple lung metastases that responded dramatically to 
nivolumab treatment after transarterial chemoembolization 
(TACE) and sorafenib failure, which are the current standard 
therapies for the advanced/metastatic stage.  
CASE REPORT
A 57-year-old male with chronic hepatitis B was referred 
to our hospital from a local clinic due to elevated serum α‐
fetoprotein (AFP) and suspicious HCC on computed to-
mography (CT). On magnetic resonance imaging, multiple 
masses in both hemiliver were well enhanced on the arterial 
phase and rapidly washed out on the portal phase, consistent 
Figure 1. Magnetic resonance imaging findings. Multiple liver masses are seen; 5.8 cm in the dome, 4.1 cm in the S3, and smaller nodules in the 
S1, 2.4 cm; S7, 0.7 cm & 1.3 cm; and S5, 0.9 cm.
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with HCC (Fig. 1). There was no evidence of extrahepatic 
metastasis. The serum AFP level was 1,109 ng/mL, and the 
protein level induced by vitamin K absence-II (PIVKA-II) 
was 5,808 mAU/mL. The initial liver function test was nor-
mal, with alanine aminotransferase 18 IU/L, total bilirubin 
1.1 mg/dL, albumin 4.1 g/dL, prothrombin time internation-
al normalized ratio of 1.00 and HBV DNA 120 IU/mL. The 
patient had no portal hypertension, encephalopathy or asci-
tes, and performance status was good, with an Eastern Coop-
erative Oncology Group score of zero. Modified Union for 
International Cancer Control was stage III, T3N0M0, and 
the Barcelona Clinic Liver Cancer (BCLC) stage was consid-
ered to be intermediate (BCLC B). Therefore, TACE was 
performed three times as a loco-regional treatment while 
confirming the treatment response. However, imaging tests 
performed to assess the TACE response detected hematoge-
nous lung metastasis and tumor thrombus in the right he-
patic vein (HV), and AFP and PIVKA-II levels elevated to 
2,575 ng/mL and 2,903 mAU/ml (Fig. 2). For systemic treat-
ment, the patient started 400 mg of sorafenib orally, twice-
daily. Sorafenib was tolerable without any severe side effects 
and was maintained for 6 weeks without dose reduction. 
However, the multiple lung metastases continued to increase 
on chest radiograph and chest CT with increased AFP and 
PIVKA-II (Fig. 3A, 4A). Also, tumor thrombus in the right 
HV slightly increased (Fig. 5A). After sorafenib failure as the 
first systemic therapy, a bi-weekly treatment with intrave-
nous nivolumab (ObdivoTM) 225 mg (3 mg/kg) was given. 
After 2 cycles (4 weeks) of nivolumab therapy, AFP and PIV-
KA-II levels decreased markedly with a significant decrease 
in the multiple lung metastases and retracted right HV 
thrombosis (Fig. 2-5). There was no drug toxicity. Six 
months after beginning nivolumab therapy, the AFP and 
PIVKA-II levels were normalized, and the multiple lung me-
tastases disappeared. The tumor response to nivolumab was 
assessed as a complete response (CR) by the modified re-
sponse evaluation criteria of the solid tumors criteria. The 
patient underwent 24 cycles of nivolumab therapy (48 weeks 
after starting nivolumab) to remove any tumor cell rem-
nants. The patient has no signs of disease recurrence 12 
months after stopping the nivolumab treatment (Fig. 2, 3).
This case report is limited to one case and did not cause 
harm to the study subject. No sensitive information was col-
lected or recorded from the subject. For this reason, institu-
Figure 2. The clinical course of serum AFP and PIVKA-II levels and the 
timing of the therapeutic methods. AFP, α‐fetoprotein; PIVKA-II, 
protein induced by vitamin K absence-II; TACE, transarterial 
chemoembolization.
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Figure 3. Chest radiographs. Follow-up after complete remission achieved, showing no recurrence of the tumor. (A) Before nivolumab therapy. 
(B) After 4 weeks of nivolumab therapy. (C) After 24 weeks of nivolumab therapy. (D) After 48 weeks of nivolumab therapy. (E) Forty-eight weeks 
after the end of treatment.
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Figure 4. Chest contrast‐enhanced computed tomography. (A) Before nivolumab therapy. (B) After 4 weeks of nivolumab therapy. (C) After 12 
weeks of nivolumab therapy.
A CB
Figure 5. Abdomen contrast‐enhanced computed tomography. (A) Before nivolumab therapy. (B) After 4 weeks of nivolumab therapy. (C) After 
12 weeks of nivolumab therapy.
A CB
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tional review board (IRB) approval was waived.
DISCUSSION
HCC is the most common form of liver cancer. However, 
treatment options are limited, with the standard options only 
adding a three-month survival benefit over a placebo. In the 
systemic treatment of advanced HCC, sorafenib has been the 
first choice of treatment since 2007.4-6 Many other agents 
have been developed after sorafenib, such as sunitinib, lini-
fanib, brivanib. However, these agents displayed no improve-
ment in the survival rate. In recent years, immunotherapy 
has been highlighted in various solid malignancies, and im-
mune-oncology has emerged in advanced HCC.15-17 Beyond 
the limits of standard therapies, immunotherapy strategies 
for advanced HCC are emerging with a number of innova-
tive drugs. Nivolumab, the first PD-1 agent which blocks in-
hibitory T cell checkpoints, have shown great promise in 
clinical trials involving melanoma, non-small cell lung can-
cer, and renal cell cancer.11-13 The CheckMate-040 study, 
which was a multi-cohort phase I/II trial that investigated 
nivolumab demonstrated that it is a promising treatment 
choice in advanced HCC.14 The study proved the efficacy and 
objective response rate in patients with intermediate-ad-
vanced HCC and Child-Pugh stage A. Additionally, 
nivolumab was well tolerated, with only 6% of patients pre-
senting serious treatment-related adverse events. Therefore, 
the Food and Drug Administration (FDA) granted nivolum-
ab conditional approval as a second-line agent for advanced 
HCC in September 2017. 
Following the favorable results of recent studies, nivolum-
ab was selected as an option for the patient discussed in this 
report. As nivolumab is not covered by the National Health 
Insurance System of Korea, its use can be expensive. Howev-
er, after a discussion, our patient was satisfied with the favor-
able results and willing to try the treatment. In our case, 
nivolumab exceeded our expectations, not only achieving CR 
of the tumor but also showing greater progression-free sur-
vival (PFS) and duration of response after the treatment was 
discontinued. During nivolumab treatment, our patient had 
excellent results without any treatment-related adverse ef-
fects. We stopped nivolumab therapy after 24 cycles (48 
weeks) based on the performance of the patient and PFS. 
Treatment costs were important in determining and main-
taining treatment. As in this case, there is still no consensus 
on how long chemotherapy, including immunotherapy, 
should be kept when CR enters. 
Recently, in the CheckMate-049 study, a phase-3 random-
ized study of nivolumab monotherapy was compared to 
sorafenib in the first-line setting. In this study, nivolumab 
did not display a statistically significant improvement in 
overall survival, which was the primary endpoint.18 However, 
nivolumab might provide favorable efficacy with a good safe-
ty profile in the context of the available targeted therapies. 
Like other malignancies, finding biomarkers that can predict 
treatment response to immunotherapy, including nivolum-
ab, is of paramount importance in advanced HCC. 19
In this report, we demonstrated CR using nivolumab for 
metastatic HCC after sorafenib failure. We hope this report 
will help expand the clinical application of immunotherapy 
and may be an alternative treatment option for treating ad-
vanced/metastatic HCC. 
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